NCT02251431View on ClinicalTrials.gov

Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Type 2 Diabetes MellitusChronic Kidney DiseaseLeft Ventricular Diastolic Dysfunction
Interventions
DRUG

BYDUREON

Exenatide-extended release, Cohorts A and B

DRUG

Placebo

Cohort A only

Trial Locations (1)

75226

Baylor Scott and White Research Institute- Baylor Heart and Vascular Hospital, Dallas

Sponsors
All Listed Sponsors
lead

Baylor Research Institute

OTHER